Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up.

@article{Vogelzang2014AntiadalimumabAA,
  title={Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up.},
  author={E H Vogelzang and Eva Linda Kneepkens and Michael T. Nurmohamed and Arno W. R. van Kuijk and Theo Rispens and Gerrit Jan J Wolbink and Charlotte L. M. Krieckaert},
  journal={Annals of the rheumatic diseases},
  year={2014},
  volume={73 12},
  pages={2178-82}
}
OBJECTIVES To investigate the relationship between antidrug antibodies (ADA), adalimumab concentrations and clinical response in patients with psoriatic arthritis (PsA) during 52 weeks of follow-up. METHODS This prospective cohort study included 103 consecutive patients with PsA. Disease Activity Score of 28 joints (DAS28), Erythrocyte Sedimentation Rate, C reactive protein and Psoriasis Area and Severity Index were assessed. Adalimumab concentrations and ADA were measured in serum trough… CONTINUE READING

From This Paper

Topics from this paper.
17 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Similar Papers

Loading similar papers…